Skip to content
    Reviews

    Review: No Survival Difference With NACT Plus Surgery vs CRT in Cervical Cancer

    Athanasiou et alThe Cochrane database of systematic reviews

    Review: No Survival Difference With NACT Plus Surgery vs CRT in Cervical Cancer
    A Cochrane systematic review evaluated whether neoadjuvant chemotherapy (NACT) followed by radical surgery is a viable alternative to primary chemoradiotherapy (CRT) for women with locally advanced cervical cancer (LACC; FIGO 2018 stage IB3/IIA2/IIB/IIIA-C/IVA). Chemoradiotherapy serves as the primary treatment for LACC, but it is accompanied by high toxicity, and access to radiotherapy infrastructure remains limited or unavailable in certain global settings.
    The systematic review included three randomised controlled trials (from four reports) comprising 1,326 women. Risk of bias was evaluated using Cochrane's RoB 1 tool, and certainty was assessed using GRADE. Synthesis using random-effects meta-analysis found that NACT followed by radical surgery may result in little to no difference in five-year overall survival compared to CRT (hazard ratio [HR] 1.11, 95% confidence interval [CI] 0.90 to 1.36; I² = 0%; 2 studies, 1,259 participants; low-certainty evidence).
    Evidence was very uncertain regarding five-year disease-free survival (HR 1.28, 95% CI 0.97 to 1.69; 1 study, 635 participants; very low-certainty evidence) and five-year progression-free survival (HR 1.37, 95% CI 1.07 to 1.75; 1 study, 626 participants; very low-certainty evidence). In terms of safety, NACT plus radical surgery probably increases grade ≥ 3 acute toxicity (risk ratio [RR] 1.82, 95% CI 1.45 to 2.29; I² = 0%; 2 studies, 1,224 participants; moderate-certainty evidence). The evidence remains very uncertain for grade ≥ 3 late toxicity (RR 0.71, 95% CI 0.50 to 1.01; 1 study, 591 participants; very low-certainty evidence). Quality of life after 24 months showed little to no difference between groups (mean difference 0.48, 95% CI -4.35 to 5.31; I² = 0%; 2 studies, 239 participants; low-certainty evidence).
    Evidence was downgraded primarily due to risk of bias, indirectness, and imprecision. The authors concluded that current evidence does not support NACT followed by radical surgery as an alternative to CRT for LACC. CRT remains the standard of care where high-quality radiotherapy is accessible; where it is unavailable, evidence remains insufficient to recommend NACT followed by radical surgery.

    Key Takeaways

    • Neoadjuvant chemotherapy followed by radical surgery probably increases grade ≥ 3 acute toxicity compared with chemoradiotherapy (RR 1.82, 95% CI 1.45 to 2.29; moderate-certainty evidence).
    • Five-year overall survival may show little to no difference between neoadjuvant chemotherapy plus radical surgery and chemoradiotherapy (HR 1.11, 95% CI 0.90 to 1.36; low-certainty evidence).
    • Five-year progression-free survival favored chemoradiotherapy (HR 1.37, 95% CI 1.07 to 1.75; very low-certainty evidence), and the authors conclude that evidence does not support neoadjuvant chemotherapy followed by radical surgery as an alternative to chemoradiotherapy for locally advanced cervical cancer.
    Read the original sourceThe Cochrane database of systematic reviews